Amylyx Pharmaceuticals, Inc.
AMLX
$3.63
-$0.045-1.23%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -37.55M | -72.70M | -72.70M | -118.79M | 4.73M |
| Total Depreciation and Amortization | 160.00K | 221.00K | 208.00K | 315.00K | 301.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.08M | 41.51M | 14.61M | 117.83M | 6.96M |
| Change in Net Operating Assets | -26.70M | -10.60M | -8.70M | 164.00K | 1.56M |
| Cash from Operations | -59.01M | -41.57M | -66.58M | -489.00K | 13.55M |
| Capital Expenditure | -20.00K | -36.18M | -89.00K | -67.00K | -356.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 65.00M | 75.00M | -28.87M | 886.00K | 21.28M |
| Cash from Investing | 64.98M | 38.82M | -28.96M | 819.00K | 20.93M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 148.00K | 491.00K | 47.00K | 1.45M | 347.00K |
| Repurchase of Common Stock | -38.00K | -411.00K | -20.00K | -1.32M | -117.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Financing | 110.00K | 80.00K | 27.00K | 131.00K | 230.00K |
| Foreign Exchange rate Adjustments | -525.00K | 236.00K | -39.00K | -110.00K | 237.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.56M | -2.44M | -95.55M | 351.00K | 34.94M |
